SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by McFarland, H F
Right arrow Articles by Reingold, S C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McFarland, H F
Right arrow Articles by Reingold, S C
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic eraa

H F McFarland

National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA, mcfarlandh{at}ninds.nih.gov

S C Reingold

National Multiple Sclerosis Society and Scientific and Clinical Review Associates, LLC, New York, NY, USA

Due to past success in testing and gaining regulatory approval for a variety of therapies in multiple sclerosis (MS), the conduct of future clinical trials has become increasingly problematic. An international workshop has met to discuss the issues facing the MS clinical trial community and to examine possible new strategies for the design of trials. Particular focus has been placed on trials that either avoid the use of a placebo because of ethical considerations or on designs that allow new therapies to be studied more rapidly or with fewer patients than needed in a conventional placebo-controlled trial. The discussions resulting from the workshop should provide a basis for the examination and implementation of innovative clinical trial designs in MS.

Key Words: !clinical trials • multiple sclerosis

Multiple Sclerosis, Vol. 11, No. 6, 669-676 (2005)
DOI: 10.1191/1352458505ms1231oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
S. C. Reingold, J. P. Steiner, C. H. Polman, J. A. Cohen, M. S. Freedman, L. Kappos, A. J. Thompson, and J. S. Wolinsky
The challenge of follow-on biologics for treatment of multiple sclerosis
Neurology, August 18, 2009; 73(7): 552 - 559.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
L. Mehta, S. Schwid, D. Arnold, G. Cutter, S Aradhye, L. Balcer, P. Calabresi, J. Cohen, P. Cole, R Glanzman, et al.
Proof of concept studies for tissue-protective agents in multiple sclerosis
Multiple Sclerosis, May 1, 2009; 15(5): 542 - 546.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J Petkau, S. Reingold, U Held, G. Cutter, T. Fleming, M. Hughes, D. Miller, H. McFarland, and J. Wolinsky
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses
Multiple Sclerosis, July 1, 2008; 14(6): 770 - 778.
[Abstract] [PDF]

Home page
 NeurologyHome page
C. H. Polman, S. C. Reingold, F. Barkhof, P. A. Calabresi, M. Clanet, J. A. Cohen, G. R. Cutter, M. S. Freedman, L. Kappos, F. D. Lublin, et al.
Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment
Neurology, March 25, 2008; 70(13_Part_2): 1134 - 1140.
[Abstract] [Full Text] [PDF]


Advertisement